Abstract
GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia. GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, stroke, and cardiovascular death), and the risk of admission to or treatment within hospital for heart failure. These drugs reduce albuminuria and slow the decline in estimated glomerular filtration rate over time, therefore delaying or preventing kidney failure. Furthermore, GLP-1 receptor agonists (eg, liraglutide and semaglutide) and the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor co-agonist tirzepatide have been approved for treatment of obesity, with clinical trials establishing benefits for various obesity-related conditions: prevention of type 2 diabetes; risk for major adverse cardiovascular events; heart failure, especially with preserved ejection fraction; regression of steatosis and prevention of fibrosis in steatotic liver disease; and symptomatic improvements in obstructive sleep apnoea and knee osteoarthritis. Current developments include the exploration of novel indications (eg, neurodegenerative diseases and substance use disorders) with suggestive evidence of efficacy, and the development of small-molecule GLP-1 receptor agonists for oral treatment to improve convenience. Dual (ie, GLP-1–glucagon and GLP- 1–amylin) and triple (ie, GIP–GLP-1–glucagon) receptor agonists activating multiple receptors promise greater efficacy than mono-agonists, especially for weight loss. However, some clinical development programmes have a high burden of adverse gastrointestinal events, and dose-escalation regimens should be optimised to reach acceptable tolerability.
References
1. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC.Exon duplication and divergence in the human preproglucagongene. Nature 1983; 304: 368–71.
2. Holst JJ, Ørskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut.FEBS Lett 1987; 211: 169–74.
3. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-likepeptide I (7–37) co-encoded in the glucagon gene is a potentstimulator of insulin release in the perfused rat pancreas.J Clin Invest 1987; 79: 616–19.
4. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-likepeptide-1 [7–36]: a physiological incretin in man. Lancet 1987;2: 1300–04.
5. Nauck MA, Abd El Aziz M, Quast DR. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-loweringmedications and basal insulin: an update including recentlydeveloped glucagon-like peptide-1 (GLP-1) receptor agonists and theglucose-dependent insulinotropic polypeptide/GLP-1 receptorco-agonist tirzepatide. Diabetes Obes Metab 2023; 25: 1361–71.
6. Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH.The new biology and pharmacology of glucagon. Physiol Rev 2017;97: 721–66.
7. Scheen AJ, Lefèbvre PJ. Glucagon, from past to present: a centuryof intensive research and controversies. Lancet Diabetes Endocrinol2023; 11: 129–38.
8. Sánchez-Garrido MA, Brandt SJ, Clemmensen C, Müller TD,DiMarchi RD, Tschöp MH. GLP-1/glucagon receptor co-agonismfor treatment of obesity. Diabetologia 2017; 60: 1851–61.
9. Finan B, Ma T, Ottaway N, et al. Unimolecular dual incretinsmaximize metabolic benefits in rodents, monkeys, and humans.Sci Transl Med 2013; 5: 209ra151.
10. Zhang Q, Delessa CT, Augustin R, et al. The glucose-dependentinsulinotropic polypeptide (GIP) regulates body weight and foodintake via CNS–GIPR signaling. Cell Metab 2021; 33: 833–844.
11. Liskiewicz A, Khalil A, Liskiewicz D, et al. Glucose-dependentinsulinotropic polypeptide regulates body weight and food intakevia GABAergic neurons in mice. Nat Metab 2023; 5: 2075–85.
12. Finan B, Yang B, Ottaway N, et al. A rationally designed monomericpeptide triagonist corrects obesity and diabetes in rodents. Nat Med2015; 21: 27–36.
13. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIPand GLP-1 receptor agonist for the treatment of type 2 diabetesmellitus: from discovery to clinical proof of concept. Mol Metab2018; 18: 3–14.
14. Frías JP, Davies MJ, Rosenstock J, et al, and the SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021; 385: 503–15.
15. Aronne LJ, Horn DB, le Roux CW, et al, and the SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025; 393: 26–36.
16. Lee MMY, Sattar N, Pop-Busui R, et al, and the SOUL Trial Investigators. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Diabetes Care 2025; 48: 846–59.
17. Pfeffer MA, Claggett B, Diaz R, et al, and the ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373: 2247–57.
18. Marso SP, Daniels GH, Brown-Frandsen K, et al, and the LEADER Steering Committee, and the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311–22.
19. Marso SP, Holst AG, Vilsbøll T. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2017; 376: 891–92.
20. Holman RR, Bethel MA, Mentz RJ, et al, and the EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377: 1228–39.
21. Hernandez AF, Green JB, Janmohamed S, et al, and the Harmony Outcomes Committees and Investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392: 1519–29.
22. Gerstein HC, Colhoun HM, Dagenais GR, et al, and the REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121–30.
23. Husain M, Birkenfeld AL, Donsmark M, et al, and the PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381: 841–51.
24. Gerstein HC, Sattar N, Rosenstock J, et al, and the AMPLITUDE-O Trial Investigators. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 2021; 385: 896–907.
25. Ruff CT, Baron M, Im K, O’Donoghue ML, Fiedorek FT, Sabatine MS. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat Med 2022; 28: 89–95.
26. Perkovic V, Tuttle KR, Rossing P, et al, and the FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024; 391: 109–21.
27. McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med 2025; 392: 2001–12.
28. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al, and the SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023; 389: 2221–32.
29. Becker RH, Stechl J, Msihid J, Kapitza C. Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes—a study in both people with type 2 diabetes and healthy subjects. Diabetes Obes Metab 2014;
16: 793–800.
30. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021; 9: 653–62.
31. Badve SV, Bilal A, Lee MMY, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2025; 13: 15–28.
32. Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med 2022; 28: 591–98.
33. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med 2025; 393: 2409–20.
34. Bonaca MP, Catarig AM, Houlind K, et al, and the STRIDE Trial Investigators. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet 2025; 405: 1580–93.
35. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab 2016; 24: 15–30.
36. Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 2017; 136: 849–70. Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 2023; 20: 463–74.
37. Buse JB, Bain SC, Mann JFE, et al, and the LEADER Trial Investigators. Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial. Diabetes Care 2020; 43: 1546–52.
38. Konig M, Riddle MC, Colhoun HM, et al. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. Cardiovasc Diabetol 2021; 20: 194.
39. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes—state-of-the-art. Mol Metab 2021; 46: 101102.
40. Mann JFE, Ørsted DD, Brown-Frandsen K, et al, and the LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377: 839–48.
41. Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018; 6: 605–17.
42. Tuttle KR, Rayner B, Lakshmanan MC, et al. Clinical outcomes by albuminuria status with dulaglutide versus insulin glargine in participants with diabetes and CKD: AWARD-7 exploratory analysis. Kidney360 2020; 2: 254–62.
43. Gerstein HC, Colhoun HM, Dagenais GR, et al, and the REWIND Investigators. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo- controlled trial. Lancet 2019; 394: 131–38.
44. Shaman AM, Bain SC, Bakris GL, et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 2022; 145: 575–85.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.